Peek Under The Hood: PTH Has 20% Upside

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the PowerShares DWA Healthcare Momentum Portfolio ETF ( PTH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $59.79 per unit.

START SLIDESHOW:
10 ETFs With Most Upside To Analyst Targets »

With PTH trading at a recent price near $49.70 per unit, that means that analysts see 20.29% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of PTH's underlying holdings with notable upside to their analyst target prices are Synergy Pharmaceuticals Inc ( SGYP), Sarepta Therapeutics Inc ( SRPT), and Nektar Therapeutics ( NKTR). Although SGYP has traded at a recent price of $5.29/share, the average analyst target is 103.21% higher at $10.75/share. Similarly, SRPT has 72.06% upside from the recent share price of $39.52 if the average analyst target price of $68.00/share is reached, and analysts on average are expecting NKTR to reach a target price of $20.57/share, which is 42.76% above the recent price of $14.41. Below is a twelve month price history chart comparing the stock performance of SGYP, SRPT, and NKTR:

SGYP, SRPT, and NKTR Relative Performance Chart

Combined, SGYP, SRPT, and NKTR represent 5.39% of the PowerShares DWA Healthcare Momentum Portfolio ETF. Below is a summary table of the current analyst target prices discussed above:

Name Symbol Recent Price Avg. Analyst 12-Mo. Target % Upside to Target
PowerShares DWA Healthcare Momentum Portfolio ETF PTH $49.70 $59.79 20.29%
Synergy Pharmaceuticals Inc SGYP $5.29 $10.75 103.21%
Sarepta Therapeutics Inc SRPT $39.52 $68.00 72.06%
Nektar Therapeutics NKTR $14.41 $20.57 42.76%

Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.

The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
Get the latest Zacks research report on SGYP — FREE
Get the latest Zacks research report on SRPT — FREE
Get the latest Zacks research report on NKTR — FREE

If you liked this article you might like

A Look at Affordable Health Care ETFs

A Look at Affordable Health Care ETFs